at-007
Small moleculeexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
4
Phase 4
0
Earliest trial started Jun 21, 2019 (NCT04117711)
Timeline
Indications
Mechanism of action
- Aldose reductaseINHIBITOR
AKR1B1 inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)Cc1nn(Cc2nc3cc(C(F)(F)F)ccc3s2)c(=O)c2cscc12- Mol. weight
- 425.41 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4650327 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07191912 | Phase 3 | Oct 31, 2025 | Applied Therapeutics, Inc. |
| NCT05397665 | Phase 2/Phase 3 (Phase 3) | Jan 1, 2022 | Applied Therapeutics, Inc., University of Iowa |
| NCT05418829 | Phase 3 | Oct 1, 2021 | Applied Therapeutics, Inc. |
| NCT04902781 | Phase 2/Phase 3 (Phase 3) | Mar 20, 2021 | Applied Therapeutics, Inc., Harvard University, University of Rochester |
| NCT04117711 | Phase 1/Phase 2 (Phase 2) | Jun 21, 2019 | Applied Therapeutics, Inc., Harvard University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Applied Therapeutics, Inc. | For profit | 5 | 5 | 2 | 2019 |
| Harvard University | Academic/Hospital | 2 | 0 | 2 | 2019 |
| University of Iowa | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Rochester | Academic/Hospital | 1 | 0 | 1 | 2021 |
4 organizations
Page 1 / 1